@article{10902/35928,
year = {2024},
url = {https://hdl.handle.net/10902/35928},
abstract = {Treatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1-35.0). Patients (N = 248) had received median 4 prior LOT (range, 2-13) at enrollment. 91 unique regimens were used in index LOT. Overall response rate was 31.9% (95% CI, 26.1-38.0), median progression-free survival (PFS) was 4.6 months (95% CI, 3.9-5.6) and median overall survival was 13.8 months (95% CI, 10.8-17.0). 152 patients (61.3%) had subsequent LOTs with 134 unique regimens, of which 78 were used in first subsequent LOT. Median PFS2 (from start of study through first subsequent LOT) was 10.8 months (95% CI, 8.4-13.0). 158 patients died on study, 67.7% due to progressive disease. Additional subgroup analyses and long-term safety summaries are reported. The high number of RWCP treatment regimens utilized and poor clinical outcomes confirm a lack of standardized treatment for TCE patients with RRMM, highlighting the need for new treatments with novel mechanisms.},
organization = {This study (ClinicalTrials.gov identifier: NCT04035226) was funded by Janssen Research & Development, LLC and Legend Biotech USA Inc. Medical writing support was provided by Andrew Marson and Sarika Pathak Sharma, PhD, of Eloquent Scientific Solutions, and funded by Janssen Global Services, LLC. The authors thank the LocoMMotion study team, including Jonathan Squire, Kensa Hatch, Lorenzo Acciarri, Henrieke Bruin, and Jeannie Kearl.},
publisher = {Nature Publishing Group},
publisher = {Leukemia, 2024, 38, 2554-2560},
title = {LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma - 2-year follow-up (final analysis)},
author = {Mateos, María-Victoria and Weisel, Katja and De Stefano, Valerio and Goldschmidt, Hartmut and Delforge, Michel and Mohty, Mohamad and Dytfeld, Dominik and Angelucci, Emanuele and Vincent, Laure and Perrot, Aurore and Benjamin, Reuben and Van de Donk, Niels W. C. J. and Ocio San Miguel, Enrique María and Roccia, Tito and Schecter, Jordan M. and Koskinen, Silva and Haddad, Imène and Strulev, Vadim and Mitchell, Lada and Buyze, Jozefien},
}